An Update On Retatrutide May 2025 .

The total pooled analysis revealed a statistically substantial percent reduction in body weight of the retatrutide group when contrasted to the placebo group after 36 weeks of therapy, with a general MD of − 14.33 (95% CI: − 18.27 to − 10.39, P retatrutide side effects cancer</a> in overweight individuals with or without diabetes. Early trials of retatrutide exposed that users might shed approximately a quarter of their body weight in under a year, making it virtually twice as effective as Ozempic.